Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ActivePassive International Equity ETF (NY:APIE)

37.31 -0.45 (-1.19%)
Streaming Delayed Price Updated: 3:44 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ActivePassive International Equity ETF

< Previous 1 2 Next >
News headline image
Novo Nordisk Shares Tumble On Q4 Miss, Weak Sales Forecast And Competition Concerns ↗
The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%. 
Via Stocktwits
News headline image
Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic ↗
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration. 
Via Stocktwits
Ryanair Turns Up Heat After Calling Press Briefing On Musk, Launches ‘Great Idiots Sale’ Taking Aim At SpaceX Owner ↗
Via Stocktwits
News headline image
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment ↗
Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. 
Via Stocktwits
Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly ↗
Via Stocktwits
Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗
Via Stocktwits
Why Did BioNTech Stock Surge 10% Pre-Market Today? ↗
Via Stocktwits
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More ↗
Via Stocktwits
Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report ↗
Via Stocktwits
News headline image
Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗
The company said that it is discontinuing the trials. 
Via Stocktwits
News headline image
Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants ↗
The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 
Via Stocktwits
Topics Death Government
News headline image
Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish ↗
Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. 
Via Stocktwits
News headline image
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
News headline image
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking ↗
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
News headline image
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ ↗
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease. 
Via Stocktwits
News headline image
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels ↗
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
News headline image
WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited ↗
The Robobus service covers 2.8 km in 12 minutes, connecting Avenue de la Porte d'Auteuil, Place de la Porte d'Auteuil, P1 Parking Carrefour des Anciens Combattants, and Village de Roland Garros. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React ↗
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi. 
Via Stocktwits
Topics Government
News headline image
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish ↗
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
News headline image
WeRide Narrows Losses In Q1, Announces $100M Share Repurchase Program: Retail’s Thrilled ↗
The China-based robotaxi company increased its total fleet size to over 1,200 units in the quarter. 
Via Stocktwits
News headline image
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes ↗
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
News headline image
Tencent Revenue Tops Forecasts On Gaming Surge, AI Ad Gains As Stock Rallies ↗
Gaming revenue grew 24% year-on-year, driven by the release of titles like ‘Dungeon & Fighter Mobile’ and ‘Delta Force.’ 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated ↗
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
News headline image
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia ↗
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
News headline image
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish ↗
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
News headline image
BYD Doubles Profit In Q1 2025 Driven By Strong Growth In Vehicle Sales: But Retail’s Unconvinced ↗
The company reported a net profit attributable to shareholders of RMB 9.15 billion ($1.26 billion) on Friday, up from RMB 4.57 billion in the corresponding quarter of 2024, and aligning with its... 
Via Stocktwits
News headline image
Saudi Aramco To Collaborate With Chinese EV Giant BYD To Achieve Breakthroughs In New Energy Vehicles ↗
The agreement was signed by Saudi Aramco Technologies Company (SATC), a wholly owned subsidiary of Aramco, and aims to leverage the research and development teams of both companies. 
Via Stocktwits
Topics Economy Electric Vehicles Government
News headline image
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved ↗
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
News headline image
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish ↗
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
News headline image
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves ↗
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland... 
Via Stocktwits
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.